Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Nanomedicine (Lond). 2015 Jul;10(12):1881–1897. doi: 10.2217/nnm.15.37

Figure 3. Theoretical plot (K = 1 to 6) and empirical data to illustrate inhibition efficiency with drug targeting pRNA (Z = 6).

Figure 3

(A) The sequence and secondary structure of wild-type pRNA of phi29 DNA packaging motor (upper panel) and inactive mutant pRNA with four bases mutation at 5´end of the DNA translocation domain serving as a model of drugged inactive pRNA (lower panel). (B) Fitting the phage assembly inhibition result by inactive mutant pRNA with the theoretical plots derived from Equation 2 matched with Z = 6 and K = 1. (C) Comparing the viral assembly inhibition effect by drugged pRNA at different concentration with the undrugged pRNA with same dilution factor.

W: With; W/O: Without.